FierceVaccines takes a holiday

Over the last several weeks, FierceVaccines has been working with data provided by Kalorama Information to take a closer look at what biopharma's pipeline holds for the future of the vaccine industry. The list of vaccine-preventable diseases stands at 26, representing a major advancement in the quality of human health. But there are many more exciting projects in the pipeline that could reduce or even eliminate some of our most challenging diseases.

We first took a look at the late-stage vaccine pipeline for diseases that are already treated with vaccines. Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer and Novartis combined control of 83.9 percent of the $22.1 billion world market for vaccines, and these drug giants have many updates to existing treatments in the works. And just last week, we profiled the exciting pipeline of vaccines for diseases that aren't currently vaccine-preventable. In the near term, developers are crafting vaccines for addiction, allergy, diabetes and a number of infectious diseases. Early-stage work includes vaccines for Alzheimer's, Ebola, hepatitis, multiple sclerosis, obesity, Parkinson's and stroke prevention, just to name a few. It's these new drugs that could help push the vaccine market value to $35 billion annually by 2014.

In the coming weeks, we'll examine the experimental cancer vaccine landscape--an area that's garnered a lot of attention from Big Pharma companies that hope to grab a slice of the burgeoning market.

P.S. FierceVaccines is being published early this week due to the Thanksgiving holiday. We will return to our regular schedule next week. Enjoy the long weekend! - Maureen (twitter | email)

Suggested Articles

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.